Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) Stock Competitors & Peer Comparison
See CUVL's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CUVL and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CUVL | $5.10 | +1.59% | 257.5M | 11.00 | $0.46 | N/A |
| RPRX | $67.30 | -0.40% | 30B | 12.82 | $5.25 | +1.38% |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| CORT | $72.77 | +1.59% | 7.9B | 207.83 | $0.35 | N/A |
| KNSA | $93.86 | +6.25% | 7.4B | 72.15 | $1.30 | N/A |
| LQDA | $44.40 | -0.20% | 4B | 32.41 | $1.37 | N/A |
| PBH | $42.98 | -3.02% | 2B | 9.72 | $4.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| LTGO | $12.60 | -3.15% | 756.1M | -4.99 | -$2.52 | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
CUVL vs RPRX Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, RPRX has a market cap of 30B. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while RPRX trades at $67.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas RPRX's P/E ratio is 12.82. In terms of profitability, CUVL's ROE is N/A, compared to RPRX's ROE of +0.10%. Regarding short-term risk, CUVL is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check RPRX's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
CUVL vs WBA Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas WBA's P/E ratio is -1.64. In terms of profitability, CUVL's ROE is N/A, compared to WBA's ROE of -0.57%. Regarding short-term risk, CUVL is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check WBA's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
CUVL vs CORT Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, CORT has a market cap of 7.9B. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while CORT trades at $72.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas CORT's P/E ratio is 207.83. In terms of profitability, CUVL's ROE is N/A, compared to CORT's ROE of +0.23%. Regarding short-term risk, CUVL is less volatile compared to CORT. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check CORT's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
CUVL vs KNSA Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, KNSA has a market cap of 7.4B. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while KNSA trades at $93.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas KNSA's P/E ratio is 72.15. In terms of profitability, CUVL's ROE is N/A, compared to KNSA's ROE of +0.17%. Regarding short-term risk, CUVL is less volatile compared to KNSA. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check KNSA's competition here
Liquidia Corporation (NASDAQ: LQDA)
CUVL vs LQDA Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, LQDA has a market cap of 4B. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while LQDA trades at $44.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas LQDA's P/E ratio is 32.41. In terms of profitability, CUVL's ROE is N/A, compared to LQDA's ROE of +1.50%. Regarding short-term risk, CUVL is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check LQDA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
CUVL vs PBH Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, PBH has a market cap of 2B. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while PBH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas PBH's P/E ratio is 9.72. In terms of profitability, CUVL's ROE is N/A, compared to PBH's ROE of +0.08%. Regarding short-term risk, CUVL is less volatile compared to PBH. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check PBH's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
CUVL vs HROWL Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas HROWL's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to HROWL's ROE of -1.04%. Regarding short-term risk, CUVL is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check HROWL's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
CUVL vs HROWM Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas HROWM's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to HROWM's ROE of -1.04%. Regarding short-term risk, CUVL is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check HROWM's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
CUVL vs LTGO Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, LTGO has a market cap of 756.1M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while LTGO trades at $12.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas LTGO's P/E ratio is -4.99. In terms of profitability, CUVL's ROE is N/A, compared to LTGO's ROE of N/A. Regarding short-term risk, CUVL is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check LTGO's competition here
Helus Pharma Inc. (NASDAQ: HELP)
CUVL vs HELP Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, HELP has a market cap of 554.1M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while HELP trades at $8.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas HELP's P/E ratio is -2.15. In terms of profitability, CUVL's ROE is N/A, compared to HELP's ROE of -0.71%. Regarding short-term risk, CUVL is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
CUVL vs SVA Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas SVA's P/E ratio is -5.68. In terms of profitability, CUVL's ROE is N/A, compared to SVA's ROE of -0.01%. Regarding short-term risk, CUVL is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check SVA's competition here
High Tide Inc. (NASDAQ: HITI)
CUVL vs HITI Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, HITI has a market cap of 235.3M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while HITI trades at $2.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas HITI's P/E ratio is -9.75. In terms of profitability, CUVL's ROE is N/A, compared to HITI's ROE of -0.36%. Regarding short-term risk, CUVL is more volatile compared to HITI. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check HITI's competition here
Electra Therapeutics Inc. (NASDAQ: ETRA)
CUVL vs ETRA Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, ETRA has a market cap of 164.6M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while ETRA trades at $7.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas ETRA's P/E ratio is -2.93. In terms of profitability, CUVL's ROE is N/A, compared to ETRA's ROE of N/A. Regarding short-term risk, CUVL is less volatile compared to ETRA. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check ETRA's competition here
TRex Bio Inc. (NASDAQ: TRXB)
CUVL vs TRXB Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, TRXB has a market cap of 110.7M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while TRXB trades at $13.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas TRXB's P/E ratio is -5.38. In terms of profitability, CUVL's ROE is N/A, compared to TRXB's ROE of N/A. Regarding short-term risk, CUVL is less volatile compared to TRXB. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check TRXB's competition here
Atlantic International Corp. (NASDAQ: ATLN)
CUVL vs ATLN Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, ATLN has a market cap of 68.6M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas ATLN's P/E ratio is -0.68. In terms of profitability, CUVL's ROE is N/A, compared to ATLN's ROE of -83.20%. Regarding short-term risk, CUVL is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check ATLN's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
CUVL vs CTOR Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, CTOR has a market cap of 47.3M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while CTOR trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas CTOR's P/E ratio is -1.08. In terms of profitability, CUVL's ROE is N/A, compared to CTOR's ROE of -1.03%. Regarding short-term risk, CUVL is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check CTOR's competition here
Retension Pharmaceuticals Inc. (NASDAQ: RTSN)
CUVL vs RTSN Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, RTSN has a market cap of 41M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while RTSN trades at $11.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas RTSN's P/E ratio is -4.19. In terms of profitability, CUVL's ROE is N/A, compared to RTSN's ROE of N/A. Regarding short-term risk, CUVL is less volatile compared to RTSN. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check RTSN's competition here
Rite Aid Corporation (NYSE: RAD)
CUVL vs RAD Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas RAD's P/E ratio is -0.05. In terms of profitability, CUVL's ROE is N/A, compared to RAD's ROE of +2.76%. Regarding short-term risk, CUVL is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
CUVL vs GLTO Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas GLTO's P/E ratio is -1.78. In terms of profitability, CUVL's ROE is N/A, compared to GLTO's ROE of -0.66%. Regarding short-term risk, CUVL is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check GLTO's competition here
Cosmos Health Inc. (NASDAQ: COSM)
CUVL vs COSM Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, COSM has a market cap of 30.8M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while COSM trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas COSM's P/E ratio is -0.41. In terms of profitability, CUVL's ROE is N/A, compared to COSM's ROE of -1.19%. Regarding short-term risk, CUVL is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check COSM's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
CUVL vs NSRX Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, NSRX has a market cap of 24.4M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while NSRX trades at $2.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas NSRX's P/E ratio is -3.93. In terms of profitability, CUVL's ROE is N/A, compared to NSRX's ROE of -1.59%. Regarding short-term risk, CUVL is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check NSRX's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
CUVL vs SCYX Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, SCYX has a market cap of 22M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while SCYX trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas SCYX's P/E ratio is -1.02. In terms of profitability, CUVL's ROE is N/A, compared to SCYX's ROE of -0.19%. Regarding short-term risk, CUVL is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check SCYX's competition here
Pomdoctor Limited (NASDAQ: POM)
CUVL vs POM Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, POM has a market cap of 15.5M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while POM trades at $1.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas POM's P/E ratio is -0.26. In terms of profitability, CUVL's ROE is N/A, compared to POM's ROE of +0.80%. Regarding short-term risk, CUVL is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check POM's competition here
Biofrontera Inc. (NASDAQ: BFRI)
CUVL vs BFRI Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, BFRI has a market cap of 12.2M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while BFRI trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas BFRI's P/E ratio is -1.49. In terms of profitability, CUVL's ROE is N/A, compared to BFRI's ROE of -1.28%. Regarding short-term risk, CUVL is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check BFRI's competition here
Azora Therapeutics, Inc. (NASDAQ: AZR)
CUVL vs AZR Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, AZR has a market cap of 10.4M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while AZR trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas AZR's P/E ratio is -0.24. In terms of profitability, CUVL's ROE is N/A, compared to AZR's ROE of N/A. Regarding short-term risk, CUVL is less volatile compared to AZR. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check AZR's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
CUVL vs CJJD Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas CJJD's P/E ratio is -0.46. In terms of profitability, CUVL's ROE is N/A, compared to CJJD's ROE of -0.25%. Regarding short-term risk, CUVL is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
CUVL vs SSY Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas SSY's P/E ratio is -2.86. In terms of profitability, CUVL's ROE is N/A, compared to SSY's ROE of -0.09%. Regarding short-term risk, CUVL is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check SSY's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
CUVL vs SCNX Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, SCNX has a market cap of 5.1M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while SCNX trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas SCNX's P/E ratio is -1.49. In terms of profitability, CUVL's ROE is N/A, compared to SCNX's ROE of -0.54%. Regarding short-term risk, CUVL is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check SCNX's competition here
Cerenome, Inc. (NASDAQ: CNSY)
CUVL vs CNSY Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, CNSY has a market cap of 4.9M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while CNSY trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas CNSY's P/E ratio is -0.15. In terms of profitability, CUVL's ROE is N/A, compared to CNSY's ROE of -3.94%. Regarding short-term risk, CUVL is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check CNSY's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
CUVL vs BGMS Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, BGMS has a market cap of 4.7M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while BGMS trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas BGMS's P/E ratio is -0.24. In terms of profitability, CUVL's ROE is N/A, compared to BGMS's ROE of -0.32%. Regarding short-term risk, CUVL is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check BGMS's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
CUVL vs MDVL Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas MDVL's P/E ratio is -0.05. In terms of profitability, CUVL's ROE is N/A, compared to MDVL's ROE of -2.39%. Regarding short-term risk, CUVL is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check MDVL's competition here
Eocene Ltd. (NASDAQ: EOCN)
CUVL vs EOCN Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, EOCN has a market cap of 2.7M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while EOCN trades at $2.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas EOCN's P/E ratio is -0.19. In terms of profitability, CUVL's ROE is N/A, compared to EOCN's ROE of N/A. Regarding short-term risk, CUVL is less volatile compared to EOCN. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check EOCN's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
CUVL vs ATNFW Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas ATNFW's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, CUVL is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check ATNFW's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
CUVL vs PAVS Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, PAVS has a market cap of 2.5M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while PAVS trades at $2.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas PAVS's P/E ratio is -0.03. In terms of profitability, CUVL's ROE is N/A, compared to PAVS's ROE of -0.46%. Regarding short-term risk, CUVL is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check PAVS's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
CUVL vs BGMSP Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, CUVL's ROE is N/A, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, CUVL is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
CUVL vs AZNH Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas AZNH's P/E ratio is 38.35. In terms of profitability, CUVL's ROE is N/A, compared to AZNH's ROE of +0.00%. Regarding short-term risk, CUVL is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check AZNH's competition here
Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP)
CUVL vs ASBP Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, ASBP has a market cap of 920.7K. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while ASBP trades at $8.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas ASBP's P/E ratio is -0.34. In terms of profitability, CUVL's ROE is N/A, compared to ASBP's ROE of +19.93%. Regarding short-term risk, CUVL is less volatile compared to ASBP. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check ASBP's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
CUVL vs BFRIW Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, BFRIW has a market cap of 796.7K. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while BFRIW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas BFRIW's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, CUVL is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check BFRIW's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
CUVL vs LFLYW Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, CUVL's ROE is N/A, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, CUVL is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check LFLYW's competition here
Aspire Biopharma Holdings, Inc. (NASDAQ: ASBPW)
CUVL vs ASBPW Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, ASBPW has a market cap of 196.7K. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while ASBPW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas ASBPW's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to ASBPW's ROE of +19.93%. Regarding short-term risk, CUVL is less volatile compared to ASBPW. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check ASBPW's competition here
ProPhase Labs, Inc. (NASDAQ: PRPH)
CUVL vs PRPH Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, PRPH has a market cap of 82.8K. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while PRPH trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas PRPH's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to PRPH's ROE of -13.59%. Regarding short-term risk, CUVL is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check PRPH's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
CUVL vs CPD Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, CPD has a market cap of 0. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas CPD's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to CPD's ROE of N/A. Regarding short-term risk, CUVL is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check CPD's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
CUVL vs IPXL Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas IPXL's P/E ratio is -10.11. In terms of profitability, CUVL's ROE is N/A, compared to IPXL's ROE of -1.16%. Regarding short-term risk, CUVL is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check IPXL's competition here
Shire plc (NASDAQ: SHPG)
CUVL vs SHPG Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas SHPG's P/E ratio is 11.35. In terms of profitability, CUVL's ROE is N/A, compared to SHPG's ROE of +0.13%. Regarding short-term risk, CUVL is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check SHPG's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
CUVL vs ESRX Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas ESRX's P/E ratio is 10.69. In terms of profitability, CUVL's ROE is N/A, compared to ESRX's ROE of +0.26%. Regarding short-term risk, CUVL is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check ESRX's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
CUVL vs OREX Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, OREX has a market cap of 0. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas OREX's P/E ratio is -0.14. In terms of profitability, CUVL's ROE is N/A, compared to OREX's ROE of -0.54%. Regarding short-term risk, CUVL is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check OREX's competition here
POZEN Inc. (NASDAQ: POZN)
CUVL vs POZN Comparison November 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 257.5M. In comparison, POZN has a market cap of 0. Regarding current trading prices, CUVL is priced at $5.10 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 11.00, whereas POZN's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to POZN's ROE of +0.61%. Regarding short-term risk, CUVL is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check POZN's competition here